Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRONEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (
NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. (“Alto” or the “Company”) (
NYSE: ANRO).
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced positive results from an independent, prospective replication study evaluating electroencephalography (EEG) biomarkers in people with schizophrenia. The study successfully replicated previous findings, demonstrating that event-related theta-band responses, particularly theta-band inter-trial coherence (ITC), robustly differentiate people with schizophrenia from healthy individuals.
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Alto Neuroscience, Inc. Investors of Upcoming DeadlineNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Alto Neuroscience, Inc. (“Alto” or the “Company”) (
NYSE: ANRO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANROFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers – ANRONEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (
NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRONEW YORK - September 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (
NYSE: ANRO) of a class action securities lawsuit.
Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANROSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRONEW YORK - September 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (
NYSE: ANRO) of a class action securities lawsuit.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANROSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO
The DJS Law Group reminds investors of a class action lawsuit against Alto Neuroscience, Inc. (“Alto” or “the Company”) (
NYSE: ANRO) for violations of the federal securities laws.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
Shareholders That Lost Money on Alto Neuroscience, Inc. (ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders That Lost Money on Alto Neuroscience, Inc. (ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreNEW YORK - September 3, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (
NYSE: ANRO) of a class action securities lawsuit.
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers – ANRONEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (
NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Alto Neuroscience, Inc. Investors of Upcoming DeadlineNEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Alto Neuroscience, Inc. (“Alto” or the “Company”) (
NYSE: ANRO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Lost Money on Alto Neuroscience, Inc. (ANRO)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
